Sector News

J&J and Actelion's potential deal fix? $260 per share for marketed meds, spinoff for pipeline

January 3, 2017
Life sciences

Would-be deal partners Johnson & Johnson and Actelion are onto their second round of talks, and this time, Actelion may just get the transaction it’s been hoping for.

The pair is hammering out a pact that would split Actelion’s commercialized meds from its R&D assets, sources tell Reuters. Actelion’s pipeline prospects would spin off into a new publicly traded company, while J&J would snap up the marketed meds with a cash offer in the neighborhood of $260 per share—slightly more than the figure the New Jersey company offered up before throwing in the towel last month.

Who would own the newly spun-off company—and whether Actelion founder and CEO Jean-Paul Clozel would run it—are still up for discussion, the sources said, but the companies could have an arrangement worked out by late this month.

Actelion, whose execs have been outspoken about their desire to stay solo, reportedly pushed J&J for a deal more complex than an outright buy when the pharma giant first came calling. But after two months-plus of back-and-forth with tough customer Clozel, J&J walked.

The move was fine by Actelion, which had another suitor in M&A-hungry Sanofi. But with the French behemoth reportedly ready to hand over $30 billion, J&J decided to get back into the mix, and Actelion returned to exclusive talks with its first-choice buyer.

The reason for that may hinge on J&J’s willingness to consider alternative deal types. Clozel, who founded the company with his wife Martine—Actelion’s chief scientific officer—after leaving an exec post at Roche, has touted Actelion’s standalone potential for years, dodging an $18.9 billion bid from fellow rare-disease drugmaker Shire and recording a 2011 triumph over activist hedge fund Elliott Advisors.

If Clozel did take the helm of the new entity, he would be able to continue presiding over a pipeline that includes candidates for pulmonary arterial hypertension—the therapeutic area that’s anchored Actelion’s success—as well as Clostridium difficile and multiple sclerosis.

J&J, meanwhile, would inherit moneymakers including Opsumit and Uptravi, meds that have stepped in to fill the void left by aging PAH star Tracleer. J&J’s own lead med, Remicade, is newly up against biosimilar competition from Pfizer in the U.S., making it an ideal time to bring in a new revenue stream.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.